Overview

This trial is active, not recruiting.

Conditions gastric cancer, pancreatic cancer
Treatment questionnaire, blood specimens
Sponsor Memorial Sloan Kettering Cancer Center
Start date August 2008
End date August 2017
Trial size 300 participants
Trial identifier NCT00745381, 08-105

Summary

The purpose of this study is to establish a neuroendocrine tumor registry. A registry is a collection of information. To create this registry, the investigators would like to get information, blood and tumor samples from people with neuroendocrine tumors. By collecting this information and material, the investigators are hoping to learn more about the genetic causes of neuroendocrine tumors. All of this will help us to better understand neuroendocrine cancer, so the investigators can find better ways to treat and diagnose this disease. DNA will be taken from the blood samples and will be used in future studies. This will be an important resource from which the investigators can study genes that may be related to a higher risk of neuroendocrine tumors.

The information collected will include medical information, family history of cancer and your answers to questions about how the cancer affects quality of life.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
This registry will be open to all patients with GEPNET or NET of unknown primary.
questionnaire, blood specimens
All participants will complete an epidemiology study questionnaire as well as a quality of life questionnaire. They will also be asked to donate blood samples. We will request participation in a tissue repository consisting of fresh frozen or paraffin embedded tissue. The repository will be of serum, plasma and tumor tissue. Follow-up will occur on patients every 6 months for the first year after consent and then annually.

Primary Outcomes

Measure
To develop a tissue, serum, plasma and DNA bank from individuals with NET. This bank will be combined with epidemiologic and clinical information to create a NET database.
time frame: conclusion of the study

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Diagnosis of gastroenteropancreatic neuroendocrine tumors or neuroendocrine tumors of unknown primary - Willing to donate blood samples - >= 18years old - Patients may have received prior hormonal therapy, cytotoxic therapy, irradiation, immunotherapy or surgical therapy Exclusion Criteria: - Have any condition, which in the opinion of the primary MSKCC clinician or investigators precludes their ability to provide informed consent

Additional Information

Official title Gastroenteropancreatic and Unknown Primary Neuroendocrine Registry A Collection of Clinical and Epidemiologic Data Combined With Tissue and Blood From Patients With a Diagnosis of Neuroendocrine Tumors
Principal investigator Diane Reidy-Lagunes, MD
Trial information was received from ClinicalTrials.gov and was last updated in August 2016.
Information provided to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center.